glaxosmithkline and vir start phase 2/3 study for covid-19 antibody drug
Published 4 years ago • 1.2K plays • Length 2:05Download video MP4
Download video MP3
Similar videos
-
1:05
vir, gsk begin phase 3 trial for covid-19 antibody drug
-
5:39
gsk chief scientist and vir ceo on clinical trial for covid-19 antibody drug
-
1:49
coronavirus treatment: glaxosmithkline partners with vir to start antibody treatment tests
-
2:38
our covid-19 antibody treatment will work against new strains: vir ceo
-
4:37
vir biotech ceo on the expanded gsk partnership
-
1:23:27
immune 30: immunology of covid-19, part two
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
1:02:09
coronaviruses 101: focus on molecular virology
-
2:04
sanofi, glaxosmithkline reach $2.1 billion deal with u.s. to supply vaccine doses
-
1:39
astrazeneca and u.s. strike deal to develop covid-19 antibody drug supply
-
8:38
vir biotechnology president and ceo explains covid-19 antibody treatment
-
1:44
glaxosmithkline ceo shoots for 'at least' six fda drug approvals in 2020
-
3:38
fda: some antibody treatments don't work against omicron, pulls emergency use authorization
-
4:59
this company working on a covid-19 treatment involving sars antibodies
-
2:35
covid vaccine by sanofi-gsk delayed after disappointing results in older patients
-
2:13
eli lilly ceo on covid antibody treatment's effectiveness against mutations
-
6:03
going all-in on infectious diseases
-
47:49
etl speaker series: george scangos, vir biotechnology
-
42:40
how mrna vaccines revolutionized medicine | cnbc marathon
-
5:02
physician breaks down differences between pfizer's and merck's covid antiviral pills
-
38:05
antibody testing for covid-19
-
42:23
evolving understanding on covid-19 vaccines and sars-cov-2 variants